Comparative Proteomic Profiling of Ectosomes Derived from Thyroid Carcinoma and Normal Thyroid Cells Uncovers Multiple Proteins with Functional Implications in Cancer.
LC–MS/MS
cancer
ectosomes
proteomics
thyroid carcinoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
31 03 2022
31 03 2022
Historique:
received:
21
02
2022
revised:
28
03
2022
accepted:
28
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Proteins carried by tumor-derived ectosomes play an important role in cancer progression, and are considered promising diagnostic markers. In the present study, a shotgun nanoLC-MS/MS proteomic approach was applied to profile and compare the protein content of ectosomes released in vitro by normal human thyroid follicular epithelial Nthy-ori 3-1 cells and human anaplastic thyroid carcinoma (TC) 8305C cells. Additionally, the pro-migratory and pro-proliferative effects of Nthy-ori 3-1- and 8305C-derived ectosomes exerted on the recipient cells were assessed in wound closure and Alamar Blue assays. A total of 919 proteins were identified in all replicates of 8305C-derived ectosomes, while Nthy-ori 3-1-derived ectosomes contained a significantly lower number of 420 identified proteins. Qualitative analysis revealed 568 proteins present uniquely in 8305C-derived ectosomes, suggesting their applicability in TC diagnosis and management. In addition, 8305C-derived ectosomes were able to increase the proliferation and motility rates of the recipient cells, likely due to the ectosomal transfer of the identified cancer-promoting molecules. Our description of ectosome protein content and its related functions provides the first insight into the role of ectosomes in TC development and progression. The results also indicate the applicability of some of these ectosomal proteins for further investigation regarding their potential as circulating TC biomarkers.
Identifiants
pubmed: 35406748
pii: cells11071184
doi: 10.3390/cells11071184
pmc: PMC8997476
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Life Sci. 2018 Aug 15;207:395-411
pubmed: 29959030
Int J Oncol. 2020 Oct;57(4):881-889
pubmed: 32945399
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514388
Endocr Relat Cancer. 2019 May;26(5):525-538
pubmed: 30870812
Int J Mol Sci. 2020 Apr 22;21(8):
pubmed: 32331267
Int J Mol Sci. 2018 Sep 05;19(9):
pubmed: 30189598
J Proteomics. 2019 Jul 30;204:103414
pubmed: 31195151
Cell Oncol (Dordr). 2019 Aug;42(4):477-490
pubmed: 30949979
Biomaterials. 2019 Jan;190-191:38-50
pubmed: 30391801
Respir Res. 2020 Jul 8;21(1):175
pubmed: 32641036
Horm Cancer. 2020 Feb;11(1):13-16
pubmed: 31838715
Thorac Cancer. 2017 Jul;8(4):337-343
pubmed: 28544512
Mol Cancer. 2019 Mar 30;18(1):55
pubmed: 30925923
Arab J Gastroenterol. 2017 Mar;18(1):1-5
pubmed: 28223105
Int J Mol Sci. 2020 Jul 28;21(15):
pubmed: 32731639
Pharmacol Ther. 2018 Aug;188:1-11
pubmed: 29476772
Cancer J. 2018 Mar/Apr;24(2):65-69
pubmed: 29601332
Endocr Relat Cancer. 2018 Oct;25(10):879-891
pubmed: 29895528
J Cancer. 2021 Apr 17;12(11):3393-3406
pubmed: 33976749
Nat Rev Cancer. 2020 Dec;20(12):697-709
pubmed: 32958932
Cancer Genomics Proteomics. 2017 01-02;14(1):53-67
pubmed: 28031237
Nat Biotechnol. 2014 Mar;32(3):223-6
pubmed: 24727771
Int J Mol Sci. 2019 Aug 02;20(15):
pubmed: 31382537
Am J Physiol Cell Physiol. 2020 Jan 1;318(1):C29-C39
pubmed: 31693397
Crit Rev Oncog. 2019;24(4):369-377
pubmed: 32421991
Trends Cancer. 2021 Feb;7(2):122-133
pubmed: 33008796
J Cell Physiol. 2019 Apr;234(4):3790-3799
pubmed: 30362517
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Trends Mol Med. 2019 Apr;25(4):315-327
pubmed: 30871809
Clin Cancer Res. 2019 May 15;25(10):3141-3151
pubmed: 30737244
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8911-8917
pubmed: 32964981
Mol Cell Endocrinol. 2020 Feb 15;502:110676
pubmed: 31812782
Pharmaceutics. 2021 Feb 10;13(2):
pubmed: 33578882
Int J Oncol. 2021 Dec;59(6):
pubmed: 34779491
Nat Methods. 2007 Nov;4(11):923-5
pubmed: 17952086
J Endocrinol. 2017 Feb;232(2):R67-R81
pubmed: 27852725
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Sci Rep. 2018 Sep 10;8(1):13509
pubmed: 30201988
Br J Cancer. 1989 Dec;60(6):897-903
pubmed: 2557880
Pharmaceutics. 2020 Sep 13;12(9):
pubmed: 32933147
Anal Chem. 2010 Mar 15;82(6):2272-81
pubmed: 20166708
Int J Mol Sci. 2021 Jun 24;22(13):
pubmed: 34202855
Cancer Lett. 2016 Sep 28;380(1):216-26
pubmed: 26238184
Endocr Connect. 2020 Jun;9(6):506-518
pubmed: 32485677
Biomed Res Int. 2013;2013:703048
pubmed: 23484144
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841521
Thyroid. 2021 May;31(5):772-786
pubmed: 33256569
J Cancer. 2021 Sep 27;12(22):6883-6893
pubmed: 34659576
Int J Biol Markers. 2015 Feb 24;30(1):e104-10
pubmed: 25262702
Semin Oncol. 2015 Apr;42(2):304-8
pubmed: 25843734
Front Immunol. 2020 Jun 12;11:1124
pubmed: 32655554
BMC Cancer. 2020 Jun 19;20(1):575
pubmed: 32560641
Front Endocrinol (Lausanne). 2020 Jun 16;11:382
pubmed: 32612576
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32459310
PLoS One. 2018 Jun 28;13(6):e0199740
pubmed: 29953504